Synonyms: TAK 165 | TAK-165 | TAK165
Compound class:
Synthetic organic
Comment: Mubritinib is a reversible inhibitor of EGFR and HER2. This compound is a Phase I clinical candidate.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Mubritinib completed a Phase 1 clinical trial in patients with HER2+ve solid tumours (NCT00034281), but development has not progressed further. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00034281 | Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 | Phase 1 Interventional | Takeda |